Table 9.
Summary of exposure routes, duration of exposure and concentrations of pure cyanotoxins applied in papers examining effects on the cardiovascular system
| Cyanotoxin | Exposure route | Number of studies | ||
|---|---|---|---|---|
| Acute | Chronic | Total | ||
| MCs | Intraperitoneal | 3 | 5* | 8 |
| Oral | − | 3** | 3 | |
| Intravenous | 2 | − | 2 | |
| Immersion | 13 | 4*** | 17 | |
| Cellular, in vitro | 9 | − | 9 | |
| NOD | Immersion | 3 | − | 3 |
| CYN | Intraperitoneal | 2 | − | 2 |
| Oral | 5 | − | 5 | |
| Immersion | 3 | − | 3 | |
| Cellular, in vitro | 3 | − | 3 | |
| ATX | Intravenous | 3 | − | 3 |
| Intracerebroventricular | 1 | − | 1 | |
| Immersion | 1 | − | 1 | |
| GNTX | Intravenous | 1 | − | 1 |
| STX | Intraperitoneal | 2 | − | 2 |
| Immersion | 2 | − | 2 | |
| Cellular, in vitro | 1 | − | 1 | |
| LTX | Cellular, in vitro | 1 | − | 1 |
| Total | 55 | 12 | 67 | |
*7 days–8 months, **7 days –6 months, ***21–60 days